V
Vijaya Kumar Daram
Publications - 3
Citations - 65
Vijaya Kumar Daram is an academic researcher. The author has contributed to research in topics: Inactivated vaccine & Immunogenicity. The author has an hindex of 2, co-authored 3 publications receiving 20 citations.
Papers
More filters
Journal ArticleDOI
Th1 Skewed immune response of Whole Virion Inactivated SARS CoV 2 Vaccine and its safety evaluation.
Brunda Ganneru,Harsh Jogdand,Vijaya Kumar Daram,Dipankar Das,Narasimha Reddy Molugu,Sai Prasad,Srinivas V. Kannappa,Krishna Murthy Ella,Rajaram Ravikrishnan,Amit Awasthi,Jomy Jose,Panduranga Rao,Deepak Kumar,Raches Ella,Priya Abraham,Pragya D Yadav,Gajanan Sapkal,Anita Shete-Aich,Gururaj Rao Desphande,Sreelekshmy Mohandas,Atanu Basu,Nivedita Gupta,Krishna Mohan Vadrevu +22 more
TL;DR: In this article, the safety and immunogenicity of a whole virion inactivated (WVI) SARS-CoV-2 vaccine (BBV152), adjuvanted with aluminum hydroxide gel (Algel), or TLR7/8 agonist chemisorbed Algel, were evaluated in mice, rats, and rabbits.
Journal ArticleDOI
Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion Inactivated SARS-CoV-2 Vaccine - BBV152
Brunda Ganneru,Harsh Jogdand,Vijaya Kumar Daram,Narasimha Reddy Molugu,Sai Prasad,Srinivas V. Kannappa,Krishna Murthy Ella,Rajaram Ravikrishnan,Amit Awasthi,Jomy Jose,Panduranga Rao,Deepak Kumar,Raches Ella,Priya Abraham,Pragya D Yadav,Gajanan Sapkal,Anita M. Shete,Gururaj Rao Desphande,Sreelekshmy Mohandas,Atanu Basu,Nivedita Gupta,Krishna Mohan Vadrevu +21 more
TL;DR: The results show that BBV152 vaccine formulations generated significantly high antigen-binding and neutralizing antibody titers, at both concentrations, in all three species with excellent safety profiles, and support further development for Phase I/II clinical trials in humans.
Patent
A process for enterovirus purification and inactivation and vaccine compositions obtained thereof
TL;DR: In this article, the present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations.